The firm saw its revenues more than quadruple year over year to $150,000, mainly due to expansion of its commercial liquid biopsy testing business.
The company is developing liquid biopsy tests to detect disease recurrence and drug resistance, but does not yet have a specific plan for its first commercial assay.
The company is embarking on a study of up to 2,000 patients to compare its tissue-based targeted sequencing assay with its cell-free DNA test.
Clinical applications for the approach are already at hand, and are poised to expand as companies solidify the clinical validity and utility data behind their platforms.
Last year, company founders published a paper in which they presented CAPP-Seq, a sensitive and inexpensive method for detecting and profiling ctDNA from cancer patients.
The company said it is shifting focus from demonstrating clinical validity to proving its test can improve patient care and outcomes.
Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.
CAPP Medical, based in Palo Alto, Calif., was founded in October 2013 by Stanford University oncologists and "industry veterans."
The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.
The partners hope to demonstrate the clinical utility of Biocept's liquid biopsy technology in improving the care of NSCLC patients.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.